Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study-Reference-Cited by-同舟云学术

Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study

Published:2022-08-17 Issue:9 Volume:42 Page:763-774
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Schreiber Ariyon^ORCID,Bauzon Justin S.^ORCID,Batra Kavita^ORCID,Mohammed Salman,Lee Kevin,Houshmand Nazanin^ORCID,Pham Uyen^ORCID,Cosme Celica^ORCID,Inciong Kim^ORCID,Al-Taweel Omar,Nasser Keaton^ORCID,Rana Jibran,Sossou Chris,Go Ariel,Hawwass Dalia,Diep Jimmy,Ahsan Chowdhury H.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-022-01187-x.pdf

Reference72 articles.

1. National Center for Biotechnology Information. PubChem Compound Summary for CID 121304016, Remdesivir. 2022; https://pubchem.ncbi.nlm.nih.gov/compound/Remdesivir. Accessed 10 Apr 2022.

2. Nabati M, Parsaee H. Potential cardiotoxic effects of remdesivir on cardiovascular system: a literature review. Cardiovasc Toxicol. 2022;22:268–72. https://doi.org/10.1007/s12012-021-09703-9.

3. Touafchia A, Bagheri H, Carrié D, Durrieu G, Sommet A, Chouchana L, Montastruc F. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clin Microbiol Infect. 2021;27:791.e5-791.e8. https://doi.org/10.1016/j.cmi.2021.02.013.

4. Pallotto C, Suardi LR, Gabbuti A, Esperti S, Mecocci L, Blanc P. Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19). J Med Virol. 2021;93:2631–4. https://doi.org/10.1002/jmv.26898.

5. Gubitosa JC, Kakar P, Gerula C, Nossa H, Finkel D, Wong K, Khatri M, Ali H. Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review. JACC Case Rep. 2020;2:2260–4. https://doi.org/10.1016/j.jaccas.2020.08.025.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center;Annals of Medicine;2024-06-03

2. An updated meta‐analysis of pooled incidence of remdesivir‐associated bradycardia;Journal of Medical Virology;2024-04

3. Remdesivir-Induced Bradycardia and Mortality in SARS-CoV-2 Infection, Potential Risk Factors Assessment: A Systematic Review and Meta-Analysis;Journal of Clinical Medicine;2023-12-05

4. Impact of Remdesivir on inflammatory and prognostic markers of COVID-19: Findings of an event-monitoring study;Journal of Family Medicine and Primary Care;2023-12

5. Precipitating factors of bradycardia after remdesivir administration: ICU admission and cutoff value for declining heart rate;Journal of Microbiology, Immunology and Infection;2023-10